Goldman Sachs Upgrades Health Net (HNT) to Buy, Cites Underlying Asset Value
Get Alerts HNT Hot Sheet
Price: $67.19 --0%
Rating Summary:
4 Buy, 11 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
4 Buy, 11 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Goldman Sachs upgraded Health Net (NYSE: HNT) from Neutral to Buy with a price target of $35, suggesting 28% upside.
The firm said the underlying asset value of the company "provides both a floor for the stock and also substantial upside potential, even as we recognize further downside risk to earnings."
Goldman sees 2012 EPS of $2.00, versus its prior view of $3.41 and below the new guidance of $2.35-$2.50. They also lower 2013/2014E EPS of $3.00/$3.50 vs. prior $3.92/$5.00.
For an analyst ratings summary and ratings history on Health Net click here. For more ratings news on Health Net click here.
Shares of Health Net closed at $27.26 yesterday.
The firm said the underlying asset value of the company "provides both a floor for the stock and also substantial upside potential, even as we recognize further downside risk to earnings."
Goldman sees 2012 EPS of $2.00, versus its prior view of $3.41 and below the new guidance of $2.35-$2.50. They also lower 2013/2014E EPS of $3.00/$3.50 vs. prior $3.92/$5.00.
For an analyst ratings summary and ratings history on Health Net click here. For more ratings news on Health Net click here.
Shares of Health Net closed at $27.26 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
- Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15
Create E-mail Alert Related Categories
Hot Upgrades, UpgradesRelated Entities
Goldman Sachs, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share